Edward H Ip1, Santiago Saldana1, Kathy D Miller2, Ruth C Carlos3, Ilana F Gareen4, Joseph A Sparano5, Noah Graham6, Fengmin Zhao6,7, Ju-Whei Lee6, Nathaniel S O'Connell1, David Cella8, John D Peipert8, Robert J Gray6,7, Lynne I Wagner9. 1. Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina. 2. Hematology/Oncology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 3. Department of Radiology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan. 4. Department of Epidemiology and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. 5. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 6. ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, Massachusetts. 7. Department of Biostatics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 8. Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 9. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Abstract
BACKGROUND: E5103 was a study designed to evaluate the efficacy and safety of bevacizumab. It was a negative trial for the end points of invasive disease-free survival and overall survival. The current work examines the tolerability of bevacizumab and other medication exposures with respect to clinical outcomes and patient-reported outcomes (PROs). METHODS: Adverse events (AEs) collected from the Common Terminology Criteria for Adverse Events were summarized to form an AE profile at each treatment cycle. All-grade and high-grade events were separately analyzed. The change in the AE profile over the treatment cycle was delineated as distinct AE trajectory clusters. AE-related and any-reason early treatment discontinuations were treated as clinical outcome measures. PROs were measured with the Functional Assessment of Cancer Therapy-Breast + Lymphedema. The relationships between the AE trajectory and early treatment discontinuation as well as PROs were analyzed. RESULTS: More than half of all AEs (57.5%) were low-grade. A cluster of patients with broad and mixed AE (all-grade) trajectory grades was significantly associated with any-reason early treatment discontinuation (odds ratio [OR], 2.87; P = .01) as well as AE-related discontinuation (OR, 4.14; P = .001). This cluster had the highest count of all-grade AEs per cycle in comparison with other clusters. Another cluster of patients with primary neuropathic AEs in their trajectories had poorer physical well-being in comparison with a trajectory of no or few AEs (P < .01). A high-grade AE trajectory did not predict discontinuations. CONCLUSIONS: A sustained and cumulative burden of across-the-board toxicities, which were not necessarily all recognized as high-grade AEs, contributed to early treatment discontinuation. Patients with neuropathic all-grade AEs may require additional attention for preventing deterioration in their physical well-being.
BACKGROUND: E5103 was a study designed to evaluate the efficacy and safety of bevacizumab. It was a negative trial for the end points of invasive disease-free survival and overall survival. The current work examines the tolerability of bevacizumab and other medication exposures with respect to clinical outcomes and patient-reported outcomes (PROs). METHODS: Adverse events (AEs) collected from the Common Terminology Criteria for Adverse Events were summarized to form an AE profile at each treatment cycle. All-grade and high-grade events were separately analyzed. The change in the AE profile over the treatment cycle was delineated as distinct AE trajectory clusters. AE-related and any-reason early treatment discontinuations were treated as clinical outcome measures. PROs were measured with the Functional Assessment of Cancer Therapy-Breast + Lymphedema. The relationships between the AE trajectory and early treatment discontinuation as well as PROs were analyzed. RESULTS: More than half of all AEs (57.5%) were low-grade. A cluster of patients with broad and mixed AE (all-grade) trajectory grades was significantly associated with any-reason early treatment discontinuation (odds ratio [OR], 2.87; P = .01) as well as AE-related discontinuation (OR, 4.14; P = .001). This cluster had the highest count of all-grade AEs per cycle in comparison with other clusters. Another cluster of patients with primary neuropathic AEs in their trajectories had poorer physical well-being in comparison with a trajectory of no or few AEs (P < .01). A high-grade AE trajectory did not predict discontinuations. CONCLUSIONS: A sustained and cumulative burden of across-the-board toxicities, which were not necessarily all recognized as high-grade AEs, contributed to early treatment discontinuation. Patients with neuropathic all-grade AEs may require additional attention for preventing deterioration in their physical well-being.
Authors: David T Eton; David Cella; Kathleen J Yost; Susan E Yount; Amy H Peterman; Donna S Neuberg; George W Sledge; William C Wood Journal: J Clin Epidemiol Date: 2004-09 Impact factor: 6.437
Authors: Nicholas J Robert; Véronique Diéras; John Glaspy; Adam M Brufsky; Igor Bondarenko; Oleg N Lipatov; Edith A Perez; Denise A Yardley; Stephen Y T Chan; Xian Zhou; See-Chun Phan; Joyce O'Shaughnessy Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Paul G Kluetz; Bindu Kanapuru; Steven Lemery; Laura Lee Johnson; Mallorie H Fiero; Karen Arscott; Yolanda Barbachano; Ethan Basch; Michelle Campbell; Joseph C Cappelleri; David Cella; Charles Cleeland; Corneel Coens; Selena Daniels; Crystal S Denlinger; Dianne L Fairclough; James R Hillard; Lori Minasian; Sandra A Mitchell; Daniel O'Connor; Sheetal Patel; Eric H Rubin; Anna Ryden; Katherine Soltys; Rajeshwari Sridhara; Gita Thanarajasingam; Galina Velikova; Stephen Joel Coons Journal: Value Health Date: 2017-11-07 Impact factor: 5.725
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Melisa L Wong; Junheng Gao; Gita Thanarajasingam; Jeff A Sloan; Amylou C Dueck; Paul J Novotny; Aminah Jatoi; Arti Hurria; Louise C Walter; Christine Miaskowski; Harvey J Cohen; William A Wood; Josephine L Feliciano; Thomas E Stinchcombe; Xiaofei Wang Journal: Oncologist Date: 2020-10-01
Authors: Giuseppe Gullo; Alex J Eustace; Alexandra Canonici; Denis M Collins; Michael J Kennedy; Liam Grogan; Oscar Breathhnach; John McCaffrey; Maccon Keane; Michael J Martin; Rajnish Gupta; Gregory Leonard; Miriam O'Connor; Paula M Calvert; Paul Donnellan; Janice Walshe; Enda McDermott; Kathleen Scott; Andres Hernando; Imelda Parker; David W Murray; Alice C O'Farrell; Ashwini Maratha; Patrick Dicker; Mairin Rafferty; Verena Murphy; Norma O'Donovan; William M Gallagher; Bonnie Ky; Dimitrios Tryfonopoulos; Brian Moulton; Annette T Byrne; John Crown Journal: Ther Adv Med Oncol Date: 2019-07-24 Impact factor: 8.168
Authors: Kathy D Miller; Anne O'Neill; William Gradishar; Timothy J Hobday; Lori J Goldstein; Ingrid A Mayer; Stuart Bloom; Adam M Brufsky; Amye J Tevaarwerk; Joseph A Sparano; Nguyet Anh Le-Lindqwister; Carolyn B Hendricks; Donald W Northfelt; Chau T Dang; George W Sledge Journal: J Clin Oncol Date: 2018-07-24 Impact factor: 44.544